Information  X 
Enter a valid email address

Alcentra EurFltRt Fd (AEFS)

  Print   

Monday 27 July, 2020

Alcentra EurFltRt Fd

Completion of Partial Redemption and Voting Rights

RNS Number : 0880U
Alcentra European Fltng Rate Inc Fd
27 July 2020
 

27 July 2020

Alcentra European Floating Rate Income Fund Limited

 

Completion of partial compulsory redemption and total voting rights

Pursuant to Alcentra European Floating Rate Income Fund Limited's (the "Company") compulsory partial redemption of its redeemable ordinary shares of no par value (the "Shares") announced on 10 July 2020, 50,486,942 Shares, approximately 55.0701% of Shares in issue, were redeemed and cancelled on 24 July 2020 and, accordingly, 41,190,725 Shares remain in issue.  The remaining Shares which have not been redeemed will trade under a new ISIN - GG00BN4CFL84 (the "New ISIN"), which will be enabled and available for transactions from 8.00 a.m. today, 27 July 2020.  CREST will automatically transfer any open transactions to the New ISIN.

The Redemption Price per Share redeemed is 89.03pence. It is expected that payments of redemption monies will be effected either through CREST (in the case of Shares held in uncertificated form) or by cheque (in the case of Shares held in certificated form) by 3 August 2020.

Each Share carries the right to 1.2 votes. Therefore the total number of voting rights in the Company is 49,428,870. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries:

Jasper Cross

BNP Paribas Securities Services S.C.A., Guernsey Branch

Tel: 01481 750850

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCRFMJTMTITBAM

a d v e r t i s e m e n t